Life Science Investing Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
Life Science Investing Incyte Announces Additional FDA Approval of Opzelura® Cream in Children Ages 2-11 with Atopic Dermatitis
Life Science Investing Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
Life Science Investing Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
Life Science Investing Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
Life Science Investing Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
UPDATE - Critical Metals Corp (NASDAQ: CRML) Secures Another Significant Tanbreez Offtake Agreement for 15% of its Production with Leading U.S. Vertically Integrated Rare Earth Company, REalloys Inc.